Rystiggo (rozanolixizumab) has been given the green light by the FDA for both anti-AChR and anti-MuSK antibody-positive gMG based on the results of the MycarinG study, which showed that treatment ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

Among 12 abstracts shared, the company highlighted pivotal Phase 3 study findings and real-world data underscoring the treatment’s promise and the ongoing unmet needs in gMG care. Key findings ...